Publicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (39)

2023

  1. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

    European Urology, Vol. 84, Núm. 2, pp. 229-241

2022

  1. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  2. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

  3. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

    Prostate, Vol. 82, Núm. 13, pp. 1237-1247

2021

  1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

    The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371

  2. Mapping the Patient-Oriented Prostate Utility Scale From the Expanded Prostate Cancer Index Composite and the Short-Form Health Surveys

    Value in Health, Vol. 24, Núm. 11, pp. 1676-1685

  3. Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

    Targeted Oncology, Vol. 16, Núm. 3, pp. 357-367

  4. Reply by Authors

    The Journal of urology, Vol. 205, Núm. 5, pp. 1371

2020

  1. Advances in urologic oncology “OncoForum”: The best of 2019

    Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596

  2. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163

  3. Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745

  4. Fe de errores a «Profilaxis farmacológica de la tromboembolia venosa en la prostatectomía radical» [Med Clin (Barc). 2020;154(4):113–118] (Medicina Clinica (2020) 154(4) (113–118), (S0025775319303513), (10.1016/j.medcli.2019.04.023))

    Medicina Clinica

  5. Impact of organ confined prostate cancer treatment on quality of life

    Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 630-636

  6. Increased urinary markers of kidney damage in the institutionalized frail elderly due to recurrent urinary tract infections

    Therapeutic Advances in Urology, Vol. 12

  7. Pharmacological venous thromboembolism prophylaxis in radical prostatectomy

    Medicina Clinica, Vol. 154, Núm. 4, pp. 113-118

  8. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

    Targeted Oncology, Vol. 15, Núm. 3, pp. 301-315

  9. The impact of time from biopsy to radical prostatectomy on Gleason score undergrading and other related factors

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 187-195

2019

  1. Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

    Actas Urologicas Espanolas, Vol. 43, Núm. 10, pp. 562-567

  2. Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group)

    Actas Urologicas Espanolas, Vol. 43, Núm. 1, pp. 4-11

2018

  1. Cáncer de próstata avanzado y calidad de vida

    Archivos Espanoles de Urologia, Vol. 71, Núm. 3, pp. 306-314